Skip to main content
. 2013 Jul 2;5:25. doi: 10.3389/fnagi.2013.00025

Figure 1.

Figure 1

(A) Plasma Aβ levels after treatment with an Aβ sequestering compound. Anti-Aβ mAbs capture soluble Aβ and form Aβ-mAb complexes, which have a much longer half-life than free Aβ alone. Therefore, total Aβ (i.e., free and bound) plasma levels rise while free Aβ levels drop rapidly but return rather quickly to normal levels due to its rapid synthesis in many tissues. (B) Binding sites on Aβ1−42 of therapeutic and diagnostic mAbs. Adapted from Johnson-Wood et al. (1997); Clarke and Shearman (2000).